Decibel Therapeutics (DBTX) – Company Press Releases
-
Moore Kuehn Encourages SOVO, DBTX, DM and ZYNE Investors to Contact Law Firm
-
Moore Kuehn Encourages CTG, KLR, ZYNE, and DBTX Investors to Contact Law Firm
-
Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm
-
Moore Kuehn Encourages DBTX, AVID, CPRI, and ARCE Investors to Contact Law Firm
-
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
-
DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals
-
DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals
-
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
-
Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
-
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
-
Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
-
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
-
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-
-
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
-
Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
-
Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
-
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
-
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
-
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
-
Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
-
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
-
Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
-
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
-
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
-
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
-
Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update
-
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
-
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
-
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
-
Decibel Therapeutics Appoints Kevin F. McLaughlin to its Board of Directors
-
Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
-
Decibel Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
-
Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics to Participate in Upcoming Investor Conferences
-
Decibel Therapeutics to Participate in Upcoming Investor Conferences
-
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
-
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
-
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
-
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
-
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
-
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
-
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
-
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Back to DBTX Stock Lookup
